Oculus Signs New Partnership Agreement With V&M Industries

Oculus Innovative Sciences (Oculus) has entered into a new strategic partnership with V&M Industries for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the US and Canada while providing Oculus with a significant percentage of those revenues.

Bob Burlingame, CEO of V&M Industries, said: “We licensed the US and Canadian rights to the Microcyn-based Vetericyn formulations for animals earlier this year and have been delighted by the initial market response. Based upon our positive ramp, I anticipate we will exceed first year projected sales for the family of Vetericyn products.

“Our team recognises that the North American retail market is hungry for compelling over-the-counter human wound care products that are clinically proven safe and effective. Based on our experience with Vetericyn, we expect to generate immediate Microcyn OTC sales while producing testimonials from satisfied customers, creating an ongoing demand from consumers.”